News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Valneva SE reported second-quarter earnings per share of $-0.39, missing analyst estimates by $0.18. The company's revenue for the quarter was $40.29 million, falling short of the consensus estimate of $44.17 million. Valneva SE's stock price has declined by -0.53% in the last 3 …
Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August 14, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the …
Sharemaestro market context Price above Trend Line 52 weeks -38.4%Valneva SE reported a wider loss in H1 2026 with product sales falling to EUR 64 million, primarily due to lower sales of IXIARO, DUKORAL, and IXCHIQ, and increased operating loss. Despite the weaker performance, the company maintained its full-year guidance and highlighted progress …
Valneva reported its half-year 2026 financial results, with total product sales of €64.0 million, reiterating its full-year guidance. The company maintained a strong cash position of €121.5 million due to disciplined management and a recent offering, while also implementing a restructuring program. Valneva anticipates …
Sharemaestro market context Price above Trend Line 52 weeks -38.7%Valneva SE (VALN) is considered 7.4% overvalued according to GuruFocus's GF Value™ metric, trading at $5.54 per share against an intrinsic value of $5.16. The company reported a 32.5% year-over-year revenue decline in the first half of 2026 and is undergoing restructuring, including workforce …
* Valneva press release [https://seekingalpha.com/pr/20617691-valneva-reports-half-year-2026-financial-results-and-provides-corporate-updates] (VALN [https://seekingalpha.com/symbol/VALN]): 1H GAAP EPS of -€0.35. * Revenue of €65.84M (-32.5% Y/Y). * Solid cash position of €121.5 million as of end June 2026. * FINANCIAL OUTLOOK * Despite the continued adverse impact of the geopolitical environment on …
Sharemaestro market context Price above Trend Line 52 weeks -38.7%TD Cowen has upgraded Valneva (NASDAQ:VALN) to a "strong-buy" rating, although other analysts have mixed views, resulting in a consensus "Moderate Buy" rating with an average price target of $11.98. The company's shares opened at $5.59, significantly below its 52-week high, and it reported …
TD Cowen has initiated coverage on Valneva SE with a Buy rating and a $12.00 price target, citing the potential of its de-risked Lyme disease vaccine (LB6V) partnered with Pfizer. Despite the stock trading significantly down and the company reporting a revenue decline in …
Valneva SE is projected to report a loss of 12 cents per share, according to this earnings preview. The full article provides more details on this financial outlook. Readers can gain unlimited access to such articles through a TradingView subscription.
Valneva SE reported total revenues exceeding €170 million for the full year 2025, with a slight decrease in product sales compared to 2024. The company achieved a significant reduction in operating cash burn, advanced its Lyme disease vaccine program with Pfizer, and successfully refinanced …
Valneva SE (VALN) presents a high-risk, high-reward investment opportunity with a potential upside of 135% based on analyst targets, despite recent financial challenges like declining revenue and negative EPS. The company, focused on vaccine development, has a robust product pipeline including candidates for Lyme …
This article provides an analysis of Valneva Se (NASDAQ: VALN), highlighting a potential shift in positive near-term sentiment and a mid-channel oscillation pattern. It details an exceptional 73.5:1 risk-reward short setup and outlines three institutional trading strategies: a Long Position Trading Strategy, a Momentum …
Valneva reported its share and voting rights data as of July 31, 2026. The company had 189,771,237 issued shares and a total of 204,363,556 voting rights, including those suspended. The number of exercisable voting rights was 204,239,234.
Valneva SE (VLA) had approximately 660 total employees worldwide as of March 2026, marking a 0.9% growth from 654 employees in 2023. The company, headquartered in Metz, France, saw its headcount decrease by 2.4% year-over-year in 2026, despite having 17 active job postings. Its …
Valneva SE (VALN) currently holds a financial score of 7.33, ranking 126 out of 385 in the Biotechnology & Medical Research industry, indicating a weak financial status but high operating efficiency. The company reported a significant year-over-year revenue decrease of 34.74% and a net …
This article provides a risk assessment for Valneva SE (VALN), detailing its current risk score, beta value, and various volatility metrics. Valneva SE has a risk assessment score of 3.63, ranking 121 out of 385 in the Biotechnology & Medical Research industry, with a …
This article provides a detailed financial overview of Valneva SE (VALN), including its stock price, market capitalization, and upcoming earnings date. It presents a comprehensive look at the company's financials through its income statement, balance sheet, and cash flow statement, spanning multiple quarters and …
This article provides a detailed revenue breakdown for Valneva SE (VALN), categorized by business segments and geographical regions for the fiscal year 2025. It highlights that IXIARO is the largest revenue contributor among business segments, and the United States leads in regional revenue for …
Sharemaestro market context Price above Trend Line 52 weeks -38.7%This document summarizes Valneva's registration filing, highlighting its business as a French vaccine developer with candidates for Lyme disease and chikungunya. It also touches on financial aspects, including an adverse opinion on internal control effectiveness and details about share outstanding and the intended use …
This article summarizes Valneva's presentation at the Jefferies Global Healthcare Conference 2026, highlighting its status as a specialty vaccine company with a strong R&D pipeline. The primary focus is on its Lyme vaccine program, which showed over 70% efficacy in Phase III trials, with …
Valneva SE generated €174.70 million in revenue last year, primarily from its Development and Commercialization of Prophylactic Vaccines segment, which contributed €174.66 million. The United States was the largest regional contributor, accounting for €53.61 million of the total revenue. These figures show a slight …
Sharemaestro market context Price above Trend Line 52 weeks -38.7%Valneva is scheduled to release its first-half 2026 consolidated financial results on August 13, 2026. A live webcast for these results will also be held on the same date at 3 p.m. CET (9 a.m. ET). This announcement was originally published by Valneva SE …
Valneva SE is set to announce its first half 2026 financial results on Thursday, August 13, 2026, through a live webcast at 3 p.m. CET/9 a.m. ET. The company will discuss its financial performance and provide a business update, with an archived version of …
Valneva SE announced it will report its first half 2026 financial results on August 13, 2026, and will host a live webcast at 3 p.m. CET / 9 a.m. ET to discuss the results and provide a business update. The specialty vaccine company focuses …
Sharemaestro market context Price above Trend Line 52 weeks -38.7%Valneva SE (FR0013280286) is relying on its Ixiaro vaccine, which protects against Japanese encephalitis, to drive demand in the travel health sector. The article details the vaccine's effectiveness, dosing, regulatory approvals in the US and Europe, and its role as a key commercial product …
Valneva's stock has hit a 52-week low due to a European Medicines Agency (EMA) warning restricting the use of its chikungunya vaccine, IXCHIQ, following reports of serious adverse reactions. This setback casts doubt on the vaccine's commercial viability, but the company is pinning its …
Valneva's IXIARO vaccine offers reliable inactivated Japanese encephalitis protection for travelers and military personnel. The article details its design, efficacy, safety, and its role as a key commercialized product in Valneva's specialty vaccine portfolio, contributing to the company's recurring revenue stream. It also discusses …
Sharemaestro market context Price above Trend Line 52 weeks -38.7%Search by ticker symbol or company name and select a result to open its chart.